Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.82 USD | -0.22% | -2.46% | +17.99% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.99% | 5.59B | |
+12.03% | 116B | |
+13.02% | 106B | |
-9.38% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.34% | 16.33B | |
+6.53% | 14.14B | |
+30.66% | 12.02B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $195.9M, vs. Street Est of $199.7M